{
    "nct_id": "NCT03086369",
    "official_title": "A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer",
    "inclusion_criteria": "* Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (Stage IV) and not amenable to resection with curative intent.\n* If present, clinically significant or symptomatic amounts of ascites should be drained prior to Day 1.\n* Have had no prior systemic treatment for metastatic disease. Prior adjuvant or neo-adjuvant chemotherapy or radiochemotherapy (other than nab-paclitaxel) is allowed if completed ≥3 months prior to enrollment and no lingering toxicities are present.\n* Prior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow.\n* Phase 2: archival tumor tissue or be willing to provide a pre-treatment biopsy.\n* Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\n* Discontinued all previous treatments for cancer ≥4 weeks prior.\n* Adequate organ function.\n* Life expectancy of at least 3 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Serious concomitant systemic disorder.\n* Have received first line treatment for metastatic pancreatic cancer.\n* Received prior treatment with nab-paclitaxel.\n* Have known central nervous system malignancy or metastasis.\n* Current hematologic malignancies.\n* Participated within the last 30 days in a clinical trial involving an investigational product.\n* Women with a positive pregnancy test or lactating.\n* Have endocrine pancreatic tumors or ampullary cancer.\n* Currently enrolled in another clinical trial.\n* Have a known additional malignancy that is progressing or required active treatment within the past 1 year.\n* Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations.\n* Are taking certain anti-coagulant medications such as warfarin and are unable to be switched to other similar medicines.",
    "miscellaneous_criteria": ""
}